Long-term safety of continuous levodopa/carbidopa infusion with ND0612: Results from the ongoing BeyoND study

被引：0
|
作者：
Poewe, W. [1 ]
Stocchi, F. [2 ]
Sopromadze, S. [3 ]
Adar, L. [3 ]
Sasson, N. [3 ]
Yardeni, T. [3 ]
Giladi, N. [4 ]
机构：
[1] Med Univ Innsbruck, Innsbruck, Austria
[2] Univ & Inst Res & Med Care IRCCS San Raffaele, Rome, Italy
[3] NeuroDerm, Rehovot, Israel
[4] Tel Aviv Univ, Neurol Inst, Tel Aviv Med Ctr, Sackler Sch Med,Sagol Sch Neurosci, Tel Aviv, Israel
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2022年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPR-017
引用
收藏
页码：181 / 181
页数：1
相关论文
共 50 条
  • [41] ND0612, a novel liquid formulation of levodopa/carbidopa for subcutaneous infusion in patients with Parkinson's disease achieves stable levodopa plasma levels when administered in low and high doses
    Giladi, Nir
    Caraco, Yoseph
    Gurevich, Tanya
    Djaldetti, Ruth
    Adar, Liat
    Cohen, Yael
    Minei, Tamar Rachmilewitz
    Oren, Sheila
    NEUROLOGY, 2017, 88
  • [42] Long-term experience with continuous duodenal levodopa-carbidopa infusion (Duodopa): report of six patients
    Raudino, F.
    Garavaglia, P.
    Pianezzola, C.
    Riboldazzi, G.
    Leva, S.
    Guidotti, M.
    Bono, G.
    NEUROLOGICAL SCIENCES, 2009, 30 (01) : 85 - 86
  • [43] First results for the BeyoND study: A phase 2b, international, open-label study evaluating long-term safety of ND0612 in patients with Parkinson's disease experiencing motor complications
    Poewe, W.
    Stocchi, F.
    Giladi, N.
    Adar, L.
    Rosenfeld, O.
    Oren, S.
    Olanow, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 63 - 63
  • [44] Enteral Levodopa/Carbidopa infusion in advanced Parkinson disease: Long-term exposure
    Nyholm, Dag
    Lewander, Tommy
    Johansson, Anders
    LeWitt, Peter A.
    Lundqvist, Christofer
    Aquilonius, Sten-Magnus
    CLINICAL NEUROPHARMACOLOGY, 2008, 31 (02) : 63 - 73
  • [45] RESULTS OF LONG-TERM TREATMENT WITH CONTROLLED-RELEASE LEVODOPA CARBIDOPA
    CEDARBAUM, JM
    HOEY, M
    KUTT, H
    MCDOWELL, FH
    ANNALS OF NEUROLOGY, 1987, 22 (01) : 145 - 145
  • [46] BouNDless: An active-controlled, randomised, double-blind, double-dummy trial of continuous subcutaneous infusion of levodopa/carbidopa with ND0612 in patients with Parkinson's disease experiencing motor complications
    Rascol, O.
    Poewe, W.
    Stocchi, F.
    Yardeni, T.
    Adar, L.
    Rosenfeld, O.
    Olanow, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 1105 - 1105
  • [47] iNDiGO: A Multicenter, Randomized, Double-blind, Placebo-controlled, Study of Continuous ND0612 Infusion with Adjunct Oral Levodopa in Fluctuating Parkinson's Disease
    LeWitt, Peter
    Stocchi, Fabrizio
    Isaacson, Stuart
    Leionen, Mika
    Rachmilewitz, Tami
    Case, Ryan
    Kieburtz, Karl
    Olanow, C. Warren
    MOVEMENT DISORDERS, 2018, 33 : S94 - S94
  • [48] INTERIM RESULTS FROM AN ONGOING, LONG-TERM, OPEN-LABEL, EFFICACY AND SAFETY STUDY OF LEVODOPA/CARBIDOPA INTESTINAL GEL IN PATIENTS WITH PARKINSON'S DISEASE AND SEVERE MOTOR FLUCTUATIONS
    Odin, P.
    Chatamra, K.
    Espay, A. J.
    Standaert, D. G.
    Fernandez, H. H.
    Benesh, J.
    Robieson, W.
    Hass, S. L.
    Lenz, R. A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2011, 18 : 241 - 241
  • [49] Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry
    Buongiorno, Mariateresa
    Antonelli, Francesca
    Camara, Ana
    Puente, Victor
    de Fabregues-Nebot, Oriol
    Hernandez-Vara, Jorge
    Calopa, Matilde
    Pascual-Sedano, Berta
    Campolongo, Antonia
    Valldeoriola, Francesc
    Tolosa, Eduardo
    Kulisevsky, Jaime
    Marti, Maria Jose
    PARKINSONISM & RELATED DISORDERS, 2015, 21 (08) : 871 - 876
  • [50] Continuous subcutaneous levodopa/ carbidopa infusion for Parkinson's disease: 3-year data from the BeyoND study
    Poewe, W.
    Stocchi, F.
    Adar, L.
    Sopromadze, S.
    Yardeni, T.
    Giladi, N.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 313 - 313
12345